San Diego, California – June 3rd, 2024 – CQDM, in collaboration with Axelys, Fonds de recherche du Québec, Génome Québec, and Médicament Québec, announces the launch of the CELLULE, a new model to support and finance the development of promising technologies based on the use of RNA. This announcement is to be made at the…
ABOUT CQDM CQDM is a biopharmaceutical research consortium whose mission is to fund the developmentof innovative tools and technologies that accelerate the development of safe and effectivedrugs. We bring together world-leading pharmaceutical organizations, several Canadianbiotech companies, the best researchers from the public and private sectors, as well as theQuébec and Canadian governments. Our collaborative approach…
ABOUT CQDM CQDM is a biopharmaceutical research consortium whose mission is to fund the developmentof innovative tools and technologies that accelerate the development of safe and effectivedrugs. We bring together world-leading pharmaceutical organizations, several Canadianbiotech companies, the best researchers from the public and private sectors, as well as theQuébec and Canadian governments. Our collaborative approach…
Cet appel à projets vise à renforcer les collaborations interprovinciales entre les universités et les PME québécoises dans le domaine de la recherche sur le cerveau. Le CQDM et Brain Canada financeront jusqu’à 82 % des dépenses admissibles pour des projets visant à améliorer la prévention, le diagnostic et le traitement des troubles cérébraux. Intéressés ? Postulez ici avant…
VVector Bio develops cutting-edge technologies to enhance the manufacturing of viral vectors for cell and gene therapy and offers research-level production services.More information on their website: https://vvectorbio.com/ We invite you to learn more about this new “Network” Members as well as the advantages related to this type of CQDM membership via this link : https://cqdm.org/en/members/
ABOUT CQDM CQDM is a biopharmaceutical research consortium whose mission is to fund the development of innovative tools and technologies that accelerate the development of safe and effective drugs. We bring together world-leading pharmaceutical organizations, several Canadian biotech companies, the best researchers from the public and private sectors, as well as the Canadian and Québec…
Montreal, April 30, 2024. – The CQDM welcomes the announcement of the creation of an innovation hub for RNA-based therapies. This important mobilizing project is made possible thanks to a financial contribution of $20.3 million from the Government of Quebec (MEIE) and granted as part of the Stratégie québécoise des sciences de la vie (SQSV) 2022-2025.…
CQDM, Roche, the Jewish General Hospital Foundation and McGill University fund research project of more than $9.4M on diabetic kidney disease Montreal, April 30, 2024 – CQDM is proud to announce the funding of a collaborative research project to identify biomarkers and therapeutic solutions for diabetic kidney disease (DKD), one of the leading causes of…
CQDM welcomes its new “Network” Member, Simmunome Inc.Simmunome untangles biological complexity by developing in silico disease models that accurately capture physiological processes to predict efficacy and safety of potential treatments. In addition, our algorithms use a comprehensive multiomic approach to discover new targets and biomarkers for a disease or a certain patient population. More information…